Salvatore Tumolo

Salvatore Tumolo

Auto-generated profile, based on publicly available information

Salvatore Tumolo

Università Cattolica del Sacro Cuore, Rome, Italy

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2026 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
TSTumolo Salvatore
Tumolo Salvatore
SPSanchez Priscila
Sanchez Priscila
Alessandro PosaAlessandro Posa
Alessandro Posa
VVVingiani Vincenzo
Vingiani Vincenzo
TBTiago Bilhim
Tiago Bilhim
Roberto IezziRoberto Iezzi
Roberto Iezzi

14 August 2026 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
AGAhmet Gunkan
Ahmet Gunkan
VOVictor Arthur Ohannesian
Victor Arthur Ohannesian
STSalvatore Tumolo
Salvatore Tumolo
SLSean Lee
Sean Lee
MLMicheal T. Lee
Micheal T. Lee
SYShamar Young
Shamar Young

15 October 2026 in CardioVascular and Interventional Radiology
Verified
Journal Article
Open access
PDF file
STSalvatore Tumolo
Salvatore Tumolo
AFAfonso Quelhas Fonseca
Afonso Quelhas Fonseca
VVVincenzo Vingiani
Vincenzo Vingiani
TBTiago Bilhim
Tiago Bilhim
HTHūseyin Saygin Tuna
Hūseyin Saygin Tuna
Purpose: To evaluate the efficacy and safety of balloon-occluded transarterial chemoembolization (B-TACE) compared with conventional (cTACE) and drug-eluting-bead transarterial chemoembolization (DEB-TACE) in patients with hepatocellular carcinoma. Materials and Methods: A systematic review and meta-analysis was conducted following PRISMA guidelines and registered in PROSPERO. PubMed, Scopus, and the Cochrane Central Register of Controlled Trials were searched to 8 February 2026 for randomized and observational studies comparing B-TACE with cTACE or DEB-TACE. Tumor response (mRECIST), overall survival, and adverse events were pooled using random-effects models; risk of bias was assessed with established tools. Results: Nine studies (one randomized, eight observational; 1534 patients) were included. Complete response, objective response, disease control, and progressive disease did not differ significantly between groups, with moderate-to-substantial heterogeneity. Baseline tumors were larger in the balloon-occluded group (mean difference 4.34 mm; 95% CI 1.18- 7.50; p = 0.014). Exploratory study-level analyses suggested greater relative B-TACE effects with larger tumors, particularly for complete response and disease control.Overall survival favored B-TACE in the two studies with extractable hazard ratios (HR 0.41; 95% CI 0.23 to 0.73; p = 0.002). Post-treatment liver enzymes, bilirubin, fever, and post-embolization syndrome did not differ significantly. Conclusion: No statistically significant differences in imaging response or safety were observed between intervention and comparator groups, while B-TACE was associated with a signal toward improved overall survival despite larger baseline tumors. Exploratory findings suggested that larger tumor size may be associated with a greater relative B-TACE effect. Given the limited evidence, these findings require confirmation in randomized controlled trials.